Ob­sE­va, des­per­ate for cash, sells rights to PhII drug in bid to ex­tend run­way, test new preg­nan­cy can­di­date

Just a few months af­ter Ob­sE­va sub­stan­tial­ly im­plod­ed over a big set­back re­lat­ing to its lead drug, lin­zagolix, the women’s health biotech is sell­ing rights …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER